Olverembatinib inhibits SARS‐CoV‐2‐Omicron variant‐mediated cytokine release in human peripheral blood mononuclear cells

Abstract

Graphical Abstract The N‐terminus domain (NTD) of the SARS‐CoV‐2 Omicron variant spike protien strongly induces multiple inflammatory molecules in human peripheral blood mononuclear cells, unaffected by the mutations observed in the NTD. Olverembatinib, a clinical‐stage multi‐kinase inhibitor, potently inhibits Omicron NTD‐mediated cytokine release.

Keywords

• cytokine storm
• SARS‐CoV‐2
• Omicron variant
• Olverembatinib
• kinase signaling